WO2002032960A3 - Methods of selecting compounds for modulation of bladder function - Google Patents

Methods of selecting compounds for modulation of bladder function Download PDF

Info

Publication number
WO2002032960A3
WO2002032960A3 PCT/US2001/032371 US0132371W WO0232960A3 WO 2002032960 A3 WO2002032960 A3 WO 2002032960A3 US 0132371 W US0132371 W US 0132371W WO 0232960 A3 WO0232960 A3 WO 0232960A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulation
methods
selecting compounds
bladder function
bladder
Prior art date
Application number
PCT/US2001/032371
Other languages
French (fr)
Other versions
WO2002032960A2 (en
Inventor
Thomas M Argentieri
Jeffrey H Sheldon
Original Assignee
Wyeth Corp
Thomas M Argentieri
Jeffrey H Sheldon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002032960(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp, Thomas M Argentieri, Jeffrey H Sheldon filed Critical Wyeth Corp
Priority to JP2002536341A priority Critical patent/JP2004529611A/en
Priority to EP01981678A priority patent/EP1328550A2/en
Priority to AU2002213308A priority patent/AU2002213308A1/en
Priority to US10/399,489 priority patent/US7160684B2/en
Priority to CA002425742A priority patent/CA2425742A1/en
Publication of WO2002032960A2 publication Critical patent/WO2002032960A2/en
Publication of WO2002032960A3 publication Critical patent/WO2002032960A3/en
Priority to US11/419,714 priority patent/US20060252104A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/341—Urinary incontinence

Abstract

The present invention involves an assay system and method of selecting compounds useful in the treatment of bladder instability and related bladder conditions through the activation of KCNQ potassium channels in the bladder smooth muscle.
PCT/US2001/032371 2000-10-17 2001-10-17 Methods of selecting compounds for modulation of bladder function WO2002032960A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002536341A JP2004529611A (en) 2000-10-17 2001-10-17 Method for selecting a composition for modulating bladder function
EP01981678A EP1328550A2 (en) 2000-10-17 2001-10-17 Methods of selecting compounds for modulation of bladder function
AU2002213308A AU2002213308A1 (en) 2000-10-17 2001-10-17 Methods of selecting compounds for modulation of bladder function
US10/399,489 US7160684B2 (en) 2000-10-17 2001-10-17 Methods of selecting compounds for modulation of bladder function
CA002425742A CA2425742A1 (en) 2000-10-17 2001-10-17 Methods of selecting compounds for modulation of bladder function
US11/419,714 US20060252104A1 (en) 2000-10-17 2006-05-22 Methods of selecting compounds for modulation of bladder function

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24107800P 2000-10-17 2000-10-17
US60/241,078 2000-10-17
US28142801P 2001-04-04 2001-04-04
US60/281,428 2001-04-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/419,714 Division US20060252104A1 (en) 2000-10-17 2006-05-22 Methods of selecting compounds for modulation of bladder function

Publications (2)

Publication Number Publication Date
WO2002032960A2 WO2002032960A2 (en) 2002-04-25
WO2002032960A3 true WO2002032960A3 (en) 2003-04-17

Family

ID=26933980

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2001/032204 WO2002032419A2 (en) 2000-10-17 2001-10-16 Methods for modulating bladder function
PCT/US2001/032371 WO2002032960A2 (en) 2000-10-17 2001-10-17 Methods of selecting compounds for modulation of bladder function

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2001/032204 WO2002032419A2 (en) 2000-10-17 2001-10-16 Methods for modulating bladder function

Country Status (23)

Country Link
US (3) US6348486B1 (en)
EP (2) EP1326597B1 (en)
JP (2) JP2004511516A (en)
KR (1) KR20030040540A (en)
CN (1) CN1287781C (en)
AR (1) AR030901A1 (en)
AT (1) ATE314061T1 (en)
AU (2) AU2002211758A1 (en)
BR (1) BR0114718A (en)
CA (2) CA2450467C (en)
CY (1) CY1105353T1 (en)
DE (1) DE60116352T2 (en)
DK (1) DK1326597T3 (en)
ES (1) ES2253432T3 (en)
HK (1) HK1056514A1 (en)
HU (1) HUP0303288A2 (en)
IL (1) IL155090A0 (en)
MX (1) MXPA03003339A (en)
NO (1) NO20031580L (en)
NZ (1) NZ525301A (en)
PL (1) PL360903A1 (en)
TW (1) TWI287984B (en)
WO (2) WO2002032419A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
WO2002080898A2 (en) * 2001-04-04 2002-10-17 Wyeth Methods for treating hyperactive gastric motility
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
WO2004035037A2 (en) * 2002-10-21 2004-04-29 Ramot At Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
JP2006524641A (en) * 2003-04-25 2006-11-02 ハー・ルンドベック・アクチエゼルスカベット Substituted indoline and indole derivatives
US20070292528A1 (en) * 2003-05-06 2007-12-20 University Hospital Of Basel Kcnma1 as a Therapeutic Target in Cancer Treatment
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
ATE324869T1 (en) * 2003-11-13 2006-06-15 Ferring Bv BLISTER PACKAGING AND SOLID DOSAGE FORM CONTAINING DESMOPRESSIN
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
WO2007084497A1 (en) * 2006-01-19 2007-07-26 Wyeth A novel rat voltage-gated potassium channel
SE0600482L (en) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Pharmaceutical composition comprising desmopressin, silica and starch
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
EP2061465B1 (en) * 2006-08-23 2013-04-10 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
MX2009005652A (en) * 2006-11-28 2009-08-07 Valeant Pharmaceuticals Int 1,4 diamino bicyclic retigabine analogues as potassium channel modulators.
DE102007012029A1 (en) 2007-03-13 2008-09-18 Grünenthal GmbH Method for identifying the agonistic activity of a target compound on a potassium channel
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
KR20140143461A (en) 2007-08-06 2014-12-16 알레간 인코포레이티드 Methods and devices for desmopressin drug delivery
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2009037707A2 (en) 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
HUE046050T2 (en) * 2008-05-21 2020-01-28 Ferring Bv Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
MX2011000636A (en) * 2008-07-18 2011-08-03 Valeant Pharmaceuticals Int Modified release formulation and methods of use.
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
EP2536394A2 (en) * 2010-02-19 2012-12-26 Medichem S.A. Stabilized phenylcarbamate derivative in solid state
JP6195906B2 (en) * 2012-04-30 2017-09-13 サイフルーア ライフ サイエンシズ インコーポレイテッド Fluorinated 2-amino-4- (benzylamino) phenylcarbamate derivatives
WO2016077724A1 (en) 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
US11358930B2 (en) 2018-04-20 2022-06-14 University of Pittsburgh—of the Commonwealth System of Higher Education Selective potassium channel agonists
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007832A1 (en) * 1997-08-12 1999-02-18 Bristol-Myers Squibb Company Kcnq potassium channels and methods of modulating same
WO1999021875A1 (en) * 1997-10-24 1999-05-06 University Of Utah Research Foundation Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies
WO2000044786A1 (en) * 1999-01-26 2000-08-03 Neurosearch A/S Novel potassium channels and genes encoding these potassium channels

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37460A (en) * 1863-01-20 Improvement in meat-broilers
GB9220570D0 (en) * 1991-10-21 1992-11-11 Ici Plc Therapeutic agent
DE4200259A1 (en) 1992-01-08 1993-07-15 Asta Medica Ag NEW 1,2,4-TRIAMINOBENZOL DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
DE19539861A1 (en) 1995-10-26 1997-04-30 Asta Medica Ag Use of 4-amino-4- (4-fluorobenzylamino) -1-ethoxy-carbonylaminobenzen for the prophylaxis and treatment of the consequences of acute and chronic cerebral low blood circulation and neurodegenerative diseases
US6277978B1 (en) * 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
DE19701694A1 (en) 1997-01-20 1998-07-23 Asta Medica Ag New modifications of the 2-amino-4- (4-fluorobenzylamino) -l-ethoxycarbonyl-aminobenzen and processes for their preparation
AU2532299A (en) * 1998-02-17 1999-08-30 Astrazeneca Uk Limited Potassium channel polypeptide
US6133275A (en) * 1998-05-06 2000-10-17 Abbott Laboratories 3-phenylpyrrolidine alpha-1 adrenergic compounds
US6794161B1 (en) * 1999-01-26 2004-09-21 Neurosearch A/S Potassium channels and genes encoding these potassium channels
IT1312224B1 (en) * 1999-03-23 2002-04-09 Cit Alcatel PRE / POST-DISTORTOR CIRCUIT, ESPECIALLY FOR MICROWAVE RADIO SYSTEMS.
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6617131B2 (en) * 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
EP1272634A1 (en) * 2000-04-03 2003-01-08 Lexicon Genetics Incorporated Human ion channel protein and polynucleotides encoding the same
US6376486B1 (en) * 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
US6455568B2 (en) * 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
WO2002015902A1 (en) * 2000-08-23 2002-02-28 Merck & Co., Inc. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6613786B2 (en) * 2001-11-02 2003-09-02 Bristol-Myers Squibb Company Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
JP2007520996A (en) * 2003-01-15 2007-08-02 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52721, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 760, 18603, 2395, 2554, 8675, 32720, 4809, 14303, 16816, 17827, 32620, 577, 619, 1423, 2158, 8263, 15402, 16209, 16386, 21165, 30911, 41897, 1643, 2543, 9626, 13 31,32409,84260,2882,8203,32678 or methods and compositions for treating urological disorders using 55,053
CA2531019A1 (en) * 2003-06-30 2005-01-06 Takeda Pharmaceutical Company Limited Preventive/remedy for urinary disturbance
WO2005025293A2 (en) * 2003-09-10 2005-03-24 Icagen, Inc. Fused ring heterocycles as potassium channel modulators
MX2007013064A (en) * 2005-04-24 2008-01-16 Wyeth Corp Methods for modulating bladder function.
WO2007084497A1 (en) * 2006-01-19 2007-07-26 Wyeth A novel rat voltage-gated potassium channel

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007832A1 (en) * 1997-08-12 1999-02-18 Bristol-Myers Squibb Company Kcnq potassium channels and methods of modulating same
WO1999021875A1 (en) * 1997-10-24 1999-05-06 University Of Utah Research Foundation Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies
WO2000044786A1 (en) * 1999-01-26 2000-08-03 Neurosearch A/S Novel potassium channels and genes encoding these potassium channels

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1990, SUGIMOTO T ET AL: "IMMUNOHISTOCHEMICAL STUDY OF A RAT MEMBRANE PROTEIN WHICH INDUCES A SELECTIVE POTASSIUM PERMEATION ITS LOCALIZATION IN THE APICAL MEMBRANE PORTION OF EPITHELIAL CELLS", XP002216452, Database accession no. PREV199089080542 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 2002 (2002-02-01), KUBOTA TOMOYUKI ET AL: "Role of KCNQ1 in the cell swelling-induced enhancement of the slowly activating delayed rectifier K+ current.", XP002216475, Database accession no. PREV200200284496 *
HUBER STEPHAN M ET AL: "Metanephrogenic mesenchyme-to-epithelium transition induces profound expression changes of ion channels.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 279, no. 1 Part 2, July 2000 (2000-07-01), pages F65 - F76, XP001106764, ISSN: 0002-9513 *
JAPANESE JOURNAL OF PHYSIOLOGY, vol. 52, no. 1, February 2002 (2002-02-01), pages 31 - 39, ISSN: 0021-521X *
JOURNAL OF MEMBRANE BIOLOGY, vol. 113, no. 1, 1990, pages 39 - 48, ISSN: 0022-2631 *
OHYA SUSUMU ET AL: "Tissue-specific gene expression of erg and KCNQ subfamilies in rat smooth muscles.", JAPANESE JOURNAL OF PHARMACOLOGY, vol. 82, no. Suppl. 1, 2000, 73rd Annual Meeting of the Japanese Pharmacological Society.;Yokohama, Japan; March 23-25, 2000, pages 135P, XP001068403, ISSN: 0021-5198 *
VALLON V ET AL: "Role of KCNE1-dependent K+ fluxes in mouse proximal tubule.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY: JASN. UNITED STATES OCT 2001, vol. 12, no. 10, October 2001 (2001-10-01), pages 2003 - 2011, XP001106730, ISSN: 1046-6673 *

Also Published As

Publication number Publication date
NO20031580L (en) 2003-06-14
MXPA03003339A (en) 2003-06-19
TWI287984B (en) 2007-10-11
KR20030040540A (en) 2003-05-22
HK1056514A1 (en) 2004-02-20
US6348486B1 (en) 2002-02-19
NO20031580D0 (en) 2003-04-08
DE60116352T2 (en) 2006-06-22
PL360903A1 (en) 2004-09-20
NZ525301A (en) 2004-10-29
WO2002032419A2 (en) 2002-04-25
US20050101004A1 (en) 2005-05-12
CA2450467C (en) 2011-05-24
US20060252104A1 (en) 2006-11-09
CN1469739A (en) 2004-01-21
CN1287781C (en) 2006-12-06
JP2004529611A (en) 2004-09-30
IL155090A0 (en) 2003-10-31
AR030901A1 (en) 2003-09-03
JP2004511516A (en) 2004-04-15
WO2002032419A3 (en) 2002-08-15
EP1326597B1 (en) 2005-12-28
DK1326597T3 (en) 2006-02-13
DE60116352D1 (en) 2006-02-02
EP1328550A2 (en) 2003-07-23
ES2253432T3 (en) 2006-06-01
AU2002213308A1 (en) 2002-04-29
CY1105353T1 (en) 2010-03-03
AU2002211758A1 (en) 2002-04-29
EP1326597A2 (en) 2003-07-16
ATE314061T1 (en) 2006-01-15
US7160684B2 (en) 2007-01-09
CA2450467A1 (en) 2002-04-25
HUP0303288A2 (en) 2004-01-28
CA2425742A1 (en) 2002-04-25
WO2002032960A2 (en) 2002-04-25
BR0114718A (en) 2003-10-14

Similar Documents

Publication Publication Date Title
WO2002032960A3 (en) Methods of selecting compounds for modulation of bladder function
WO2001010381A3 (en) Methods for treating or preventing pain and anxiety
EP1587574A4 (en) SELECTIVE 11b-HSD INHIBITORS AND METHODS FOR USE THEREOF
AU2002363138A1 (en) System and method for establishing or modifying an account with user selectable terms
AU2003248331A1 (en) Hybrid membrane, method for producing the same and use of said membrane
AU2002324861A1 (en) Method and apparatus for dynamic client-side load balancing system
AU2001289188A1 (en) Audio converter device and method for using the same
AU2002320434A1 (en) Method and apparatus for enabling and rewarding wireless resource sharing
WO2003082208A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
AU2994097A (en) Regenerable catalyzed trap and apparatus, and method of using the same
WO2002074293A3 (en) Methods for restoring cognitive function following systemic stress
HUP0402278A3 (en) Microorganism for the biological detoxification of mycotoxins, namely ochratoxins and/or zearalenones, and corresponding method and use
EP1250954A3 (en) Microchannel device, method for producing the microchannel device and use of the same
AU2002356311A1 (en) Anchor for vehicle, vehicle and anchor in combination, and method of using the anchor
ZA200203253B (en) Methods and kits for treating depression or preventing deterioration of cognitive function.
HUP0103009A3 (en) Sorbent, method for producing the same and use of the same for immobilisation of heavy metals and phosphates
EP1262264A4 (en) Thrust converter, and method and device for controlling the thrust converter
AU2001236310A1 (en) System and method for wireless team-oriented voice messages of the invention
AU2002320463A1 (en) Self-regulating microfluidic device and method of using the same
AU2001256357A1 (en) Method comprising the indirect electrochemical regeneration of nad(p)h
AU2001244834A1 (en) Novel strain for decomposing tmah, and method of wastewater treatment using the same
AU2001272578A1 (en) Precalendering method, finishing method and apparatus for implementing the methods
AU2002366898A1 (en) Method and control system for the voice control of an appliance
WO2003093948A3 (en) Dynamic human resources knowledge base and process
WO2005048044A3 (en) Systems and methods for dynamic network channel modification

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2425742

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10399489

Country of ref document: US

Ref document number: 2002536341

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001981678

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001981678

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642